Proteome Sciences PLC Appointment of Chief Financial Officer (3695W)

TIDMPRM

RNS Number : 3695W

Proteome Sciences PLC

18 August 2022

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Appointment of Chief Financial Officer

The Board of Proteome Sciences plc is pleased to announce that Abdelghani Omari has been appointed as the Company's new Chief Financial Officer. He will take up the position on September 1st, 2022 and will become a director of the Company.

Abdel joins Proteome Sciences from Paion AG, a listed speciality pharmaceutical company, where he has been CFO and since 2014 a member of the management board. During his time at Paion he has negotiated numerous license agreements with pharma companies and has raised more than 150 million Euros in financing from investors in the U.S. and in Europe. In addition to the finance role, Abdel was also responsible for HR, IT, Legal, IP & Compliance and more recently investor relations. Abdel has more than 20 years' experience in finance, starting his career at KPMG Audit after a business degree from the University of Aachen. At KPMG he worked in audit and financial consultancy roles prior to joining Paion.

Proteome Sciences' Chief Executive Officer, Dr Mariola Soehngen, commented "The Board and the Company welcome Abdel as Proteome Sciences' CFO at this important point in the company's growth. Abdel brings a wealth of relevant experience to the team as we pursue the Company's strategy of organic growth, to grow the business through adding new high value services to our portfolio and enter into further internationalisation of the business.

Commenting on his appointment, Abdel said "I am very excited to join Proteome Sciences at this stage. The Company has a unique technology and highly skilled and committed people. Proteome Sciences has an exciting journey ahead and I am pleased to be joining the Company as we shape and accelerate its future growth."

As part of Mr Omari's remuneration package, three months after his appointment he will be granted 4,000,000 options under the Company's share option scheme ("Options"). The Options will be exercisable at the market price on the day of award per Option and will vest in three equal annual tranches on 1 September 2023, 1 September 2024 and 1 September 2025. Each Option is exercisable into one Ordinary Share and once vested, can be exercised up until the 10th anniversary.

Pursuant to Schedule 2 (g) of the AIM Rules for Companies, Mr Abdelghani Omari (aged 45) has held the following directorships or partnerships in the past five years:

 
 Current              Previous 
 Paion AG, Germany,   Paion Inc, USA 
  Pharma               Paion Scandic, Aps, 
  Paion Holdings UK    Denmark 
  Ltd, UK 
  Paion UK Ltd, UK 
  TheraSci Ltd, UK 
  Paion Netherlands 
  B.V. 
                     ---------------------

There is no further information on Abdelghani Omari required to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies.

For further information:

 
 Proteome Sciences plc 
 Proteome Sciences plc 
 Dr Mariola Soehngen, Chief Executive         Tel: +44 (0)20 7043 2116 
  Officer 
 Dr Ian Pike, Chief Scientific Officer 
 Richard Dennis, Chief Commercial Officer 
 Allenby Capital Limited (AIM Nominated Adviser & Broker) 
 John Depasquale / Jeremy Porter (Corporate   Tel: +44 (0) 20 3328 5656 
  Finance) 
  Tony Quirke (Sales)

About Proteome Sciences plc. ( www.proteomics.com )

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant(R) and TMT(R) MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator(TM) provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

The Company has its headquarters in Cobham, UK, with laboratory facilities in Frankfurt, Germany.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAZDLFFLVLBBBE

(END) Dow Jones Newswires

August 18, 2022 02:00 ET (06:00 GMT)

Proteome Sciences (AQSE:PRM.GB)
過去株価チャート
から 11 2024 まで 12 2024